A comparison of dabigatran etexilate with warfarin in patients with mechanical heart valves: The Randomized, phase II study to Evaluate the sAfety and pharmacokinetics of oraL dabIGatran etexilate in patients after heart valve replacemeNt (RE-ALIGN)

American Heart Journal

Volumn 163, Issue 6, 2012, Pages

  Van De Werf, Frans ^a   Brueckmann, Martina ^b   Connolly, Stuart J ^c   Friedman, Jeffrey ^d   Granger, Christopher B ^e   Härtter, Sebastian ^b   Harper, Ruth ^f   Kappetein, Arie Pieter ^g   Lehr, Thorsten ^b   Mack, Michael J ^h   Noack, Herbert ^b   Eikelboom, John W ^c  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^c MCMASTER UNIVERSITY   (Canada)

^d BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

^e DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^f BOEHRINGER INGELHEIM LTD   (United Kingdom)

^g ERASMUS MEDICAL CENTER   (Netherlands)

^h Heart Hospital Baylor   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DABIGATRAN ETEXILATE; WARFARIN;

ADULT; AGED; AORTA VALVE; AORTA VALVE REPLACEMENT; ARTICLE; CONTROLLED STUDY; CREATININE CLEARANCE; DRUG BLOOD LEVEL; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EMBOLISM; HEART VALVE PROSTHESIS; HOSPITALIZATION; HUMAN; MITRAL VALVE; OPEN STUDY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STROKE; THROMBOSIS;

EID: 84862585771     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2012.03.011     Document Type: Article

References (25)

1. Sun JC, Davidson MJ, Lamy A, et al. Antithrombotic management of patients with prosthetic heart valves: current evidence and future trends. Lancet 2009;374:565-76.
2. Cannegieter SC, Rosendaal FR, Briet E. Thromboembolic and bleeding complications in patients with mechanical heart valve prostheses. Circulation 1994;89:635-41. (Pubitemid 24056190)
3. Eitz T, Schenk S, Fritzsche D. International normalized ratio selfmanagement lowers the risk of thromboembolic events after prosthetic heart valve replacement. Ann Thorac Surg 2008;85:949-55. (Pubitemid 351253494)
4. Meijer K, Kim YK, Schulman S. Decreasing warfarin sensitivity during the first three months after heart valve surgery: implications for dosing. Thrombosis Research 2010;125:224-9.
5. Huth C, Friedl A, Rost A. Intensity of oral anticoagulation after implantation of St. Jude aortic prosthesis: analysis of the GELIA database (GELIA 4). Eur Heart J 2001(Suppl 3: Supplement Q):Q33-8.
6. Butchart EG. Antithrombotic management in patients with prosthetic valves: a comparison of American and European guidelines. Heart 2009;95:430-6.
7. Stassano P, Di Tommaso L, Monaco M. Aortic valve replacement: a prospective randomized evaluation of mechanical versus biological valves in patients ages 55 to 70 years. J Am Coll Cardiol 2009;54:1862-8.
8. Stangier J, Eriksson BI, Dahl OE. Pharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers and patients undergoing total hip replacement. J Clin Pharmacol 2005;45:555-63. (Pubitemid 40562946)
9. Stangier J. Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatranetexilate. ClinPharmacokinet 2008;47:285-95. (Pubitemid 351508116)
10. Lehr T, Haertter S, Liesenfeld KH, et al. Dabigatran etexilate in atrial fibrillation patients with severe renal impairment: dose identification-using pharmacokinetic modeling and simulation. J Clin Pharmacol 2011. doi:10.1177/0091270011417716 [published online September 28].
11. Liesenfeld KH, Lehr T, Dansirikul C, et al. Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatranetexilate in patients with non-valvular atrial fibrillation from the RE-LY trial. J Thromb-Haemost 2011;9:2168-75.
12. Dansirikul C, Lehr T, Liesenfeld KH, et al. A combined pharmacometric analysis of dabigatran etexilate in healthy volunteers and patients with atrial fibrillation or undergoing orthopaedic surgery. Thrombosis and Haemostasis 2012;107:775-85.
13. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361:1139-51.
14. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Newly identified events in the RE-LY trial. N Engl J Med 2010;363:1875-6.
15. Eikelboom JW, Wallentin L, Connolly SJ. The risk of bleeding with two doses of dabigatran compared to warfarin in older and younger patients with atrial fibrillation: An analysis of the RE-LY trial. Circulation 2011;123:2363-72.
16. Schulman S, Kearon C, Kakkar AK, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. New Engl J Med 2009;361:2342-52.
17. Schulman S, Kakkar AK, Schellong SM. A randomized trial of dabigatran versus warfarin in the treatment of acute venous thromboembolism (RE-COVER II). 53rd ASH Annual Meeting and Exhibition, December 12th: Abstract No. 205; 2011.
18. McKellar SH, Abel S, Camp CL, et al. Effectiveness of dabigatranetexilate for thromboprophylaxis ofmechanical heart valves. J ThoracCardiovascSurg 2011;141:1410-6.
19. Torn M, Cannegieter SC, Bollen WLEM. Optimal level of oral anticoagulant therapy for the prevention of arterial thrombosis in patients with mechanical heart valve prostheses, atrial fibrillation, or myocardial infarction. Arch Intern Med 2009;169:1203-9.
20. Boehringer Ingelheim. Advisory committee briefing document.www.fda.gov/ downloads/AdvisoryCommittees/CommitteesMeetingMaterialsDrugs/ CardiovascularandRenalDrugsAdvisoryCommittee/UCM226009.pdf. Last accessed 24 August 2011.
21. Vahanian A, Baumgartner H, Bax J, et al. Guidelines on the management of valvular heart disease: the task force on the management of valvular heart disease of the European Society of Cardiology. Eur Heart J 2007;28:230-68. (Pubitemid 46276943)
22. Salem DN, O'Gara PT, Madias C, et al. Valvular and structural heart disease: American College of Chest Physicians evidence-based clinical practice guidelines (8th Edition). Chest 2008;133(6 Suppl):593S-629S. (Pubitemid 351892973)
23. Bonow RO, Carabello BA, Chatterjee K, et al. 2008 focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (Writing Committee to revise the 1998 guidelines for the management of patients with valvular heart disease). Circulation 2008;118:e523-661.
24. Schulman S, Kearon C, Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in nonsurgical patients. J ThrombHaemost 2005;3:692-4. (Pubitemid 41647882)
25. Leon MB, Piazza N, Nikolsky E, et al. Standardized end point definitions for transcatheter aortic valve implantation clinical trials: a consensus report from the Valve Academic Research Consortium. Eur Heart J 2011;32:205-17.